Is population-based glaucoma screening cost-effective in China?

Lancet Glob Health. 2019 Jul;7(7):e833-e834. doi: 10.1016/S2214-109X(19)30229-3. Epub 2019 May 20.

Authors

Lei Zhang¹, Mingguang He²

Affiliations

¹ Department of Epidemiology and Biostatistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China.
² Centre for Eye Research Australia, Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, VIC 3002, Australia; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China. Electronic address: mingguang.he@unimelb.edu.au.

PMID: 31122903
DOI: 10.1016/S2214-109X(19)30229-3

No abstract available

Publication types

Comment

MeSH terms

China
Cost-Benefit Analysis
Glaucoma*
Humans
Mass Screening*